Literature DB >> 30740431

Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?

Alessandro Leonetti1,2, Francesco Facchinetti3, Marcello Tiseo1,4.   

Abstract

Entities:  

Year:  2018        PMID： 30740431      PMCID： PMC6330596          DOI： 10.21037/atm.2018.11.69

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  25 in total

1.  Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.

Authors:  T Iuchi; M Shingyoji; T Sakaida; K Hatano; O Nagano; M Itakura; H Kageyama; S Yokoi; Y Hasegawa; K Kawasaki; T Iizasa
Journal:  Lung Cancer       Date:  2013-08-28       Impact factor: 5.705

2.  Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.

Authors:  Yosuke Togashi; Katsuhiro Masago; Satohiro Masuda; Tomoyuki Mizuno; Masahide Fukudo; Yasuaki Ikemi; Yuichi Sakamori; Hiroki Nagai; Young Hak Kim; Toshiya Katsura; Michiaki Mishima
Journal:  Cancer Chemother Pharmacol       Date:  2012-07-18       Impact factor: 3.333

3.  Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

Authors:  R Porta; J M Sánchez-Torres; L Paz-Ares; B Massutí; N Reguart; C Mayo; P Lianes; C Queralt; V Guillem; P Salinas; S Catot; D Isla; A Pradas; A Gúrpide; J de Castro; E Polo; T Puig; M Tarón; R Colomer; R Rosell
Journal:  Eur Respir J       Date:  2010-07-01       Impact factor: 16.671

Review 4.  EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.

Authors:  Yu Yang Soon; Cheng Nang Leong; Wee Yao Koh; Ivan Weng Keong Tham
Journal:  Radiother Oncol       Date:  2015-01-09       Impact factor: 6.280

5.  Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

Authors:  Deepa Rangachari; Norihiro Yamaguchi; Paul A VanderLaan; Erik Folch; Anand Mahadevan; Scott R Floyd; Erik J Uhlmann; Eric T Wong; Suzanne E Dahlberg; Mark S Huberman; Daniel B Costa
Journal:  Lung Cancer       Date:  2015-02-04       Impact factor: 5.705

6.  Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

Authors:  Jessica J Lin; Stephanie Cardarella; Christine A Lydon; Suzanne E Dahlberg; David M Jackman; Pasi A Jänne; Bruce E Johnson
Journal:  J Thorac Oncol       Date:  2015-12-25       Impact factor: 15.609

7.  Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.

Authors:  Katsuyuki Hotta; Katsuyuki Kiura; Hiroshi Ueoka; Masahiro Tabata; Keiichi Fujiwara; Toshiyuki Kozuki; Toshiaki Okada; Akiko Hisamoto; Mitsune Tanimoto
Journal:  Lung Cancer       Date:  2004-11       Impact factor: 5.705

8.  Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI.

Authors:  Akito Hata; Nobuyuki Katakami; Hiroshige Yoshioka; Reiko Kaji; Katsuhiro Masago; Shiro Fujita; Yukihiro Imai; Akihiro Nishiyama; Tadashi Ishida; Yoshihiro Nishimura; Yasushi Yatabe
Journal:  J Thorac Oncol       Date:  2015-11       Impact factor: 15.609

9.  Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).

Authors:  Y-L Wu; C Zhou; Y Cheng; S Lu; G-Y Chen; C Huang; Y-S Huang; H-H Yan; S Ren; Y Liu; J-J Yang
Journal:  Ann Oncol       Date:  2012-11-04       Impact factor: 32.976

10.  Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.

Authors:  Petra Hoffknecht; Amanda Tufman; Thomas Wehler; Theo Pelzer; Rainer Wiewrodt; Martin Schütz; Monika Serke; Jan Stöhlmacher-Williams; Angela Märten; Rudolf Maria Huber; Nicolas J Dickgreber
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609
View more
  4 in total

Review 1.  Clinical Perspectives in Brain Metastasis.

Authors:  Krutika Deshpande; Ian Buchanan; Vahan Martirosian; Josh Neman
Journal:  Cold Spring Harb Perspect Med       Date:  2020-06-01       Impact factor: 5.159

2.  Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment.

Authors:  Xin Tang; Yuan Li; Wei-Feng Yan; Wen-Lei Qian; Tong Pang; You-Ling Gong; Zhi-Gang Yang
Journal:  Front Oncol       Date:  2021-09-29       Impact factor: 6.244

Review 3.  Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Authors:  Alessandro Leonetti; Sugandhi Sharma; Roberta Minari; Paola Perego; Elisa Giovannetti; Marcello Tiseo
Journal:  Br J Cancer       Date:  2019-09-30       Impact factor: 7.640

4.  Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma.

Authors:  Hualin Chen; Meilian Liu; Zhiwei Dai; Shujun Li; Yiping Luo; Yongcun Wang; Wenmei Su; Weijing Cai; Donghong Yang; Jian Huang; Zhixiong Yang
Journal:  Transl Lung Cancer Res       Date:  2020-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.